Page 14 - Read Online

Page 10 of 12 Chen et al. Rare Dis Orphan Drugs J 2022;1:15 https://dx.doi.org/10.20517/rdodj.2022.18

8. Lomas DA, Evans DL, Stone SR, Chang WS, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of alpha
1-antitrypsin. Biochemistry 1993;32:500-8. DOI PubMed
9. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte
elastase. Am Rev Respir Dis 1977;116:469-75. DOI PubMed
10. Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-
antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981;68:1158-65. DOI PubMed PMC
11. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N
Engl J Med 1987;316:1055-62. DOI PubMed
12. Stockley RA, Dirksen A, Stolk J. Alpha-1 antitrypsin deficiency: the European experience. COPD 2013;10 Suppl 1:50-3. DOI
PubMed
13. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients
with severe hereditary alpha1-antitrypsin deficiency? Eur Respir J 1997;10:2260-3. DOI PubMed
14. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-antitrypsin deficiency registry
study group. Am J Respir Crit Care Med 1998;158:49-59. DOI
15. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit
Care Med 1999;160:1468-72. DOI PubMed
16. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in
alpha1-antitrypsin deficiency. Eur Respir J 2009;33:1345-53. DOI PubMed
17. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of α-1 antitrypsin augmentation therapy on
the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res
2010;11:136. DOI PubMed PMC
18. Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin
deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. The Lancet 2015;386:360-8. DOI PubMed
19. Stockley RA. Measurement of soluble proteins in lung secretions. Thorax 1984;39:241-7. DOI PubMed PMC
20. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest
1991;87:2207-15. DOI PubMed PMC
21. Morrison HM, Welgus HG, Stockley RA, Burnett D, Campbell EJ. Inhibition of human leukocyte elastase bound to elastin: relative
ineffectiveness and two mechanisms of inhibitory activity. Am J Respir Cell Mol Biol 1990;2:263-9. DOI PubMed
22. Korkmaz B, Attucci S, Jourdan ML, Juliano L, Gauthier F. Inhibition of neutrophil elastase by alpha1-protease inhibitor at the surface
of human polymorphonuclear neutrophils. J Immunol 2005;175:3329-38. DOI PubMed
23. Sinden NJ, Baker MJ, Smith DJ, Kreft JU, Dafforn TR, Stockley RA. α-1-antitrypsin variants and the proteinase/antiproteinase
imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2015;308:L179-90. DOI PubMed PMC
24. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in
alpha 1-antitrypsin deficiency. J Clin Invest 1999;104:337-44. DOI PubMed PMC
25. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation
of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med
1999;160:1968-75. DOI
26. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that
produces emphysema in hamsters. J Clin Invest 1988;82:1963-73. DOI PubMed PMC
27. Stockley R. Neutrophils and Protease/Antiprotease Imbalance. Am J Respir Crit Care Med 1999;160:S49-52. DOI PubMed
28. Damiano VV, Tsang A, Kucich U, et al. Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 1986;78:482-
93. DOI PubMed PMC
29. Carter RI, Mumford RA, Treonze KM, et al. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase
activity in vivo. Thorax 2011;66:686-91. DOI PubMed
30. Carter RI, Ungurs MJ, Pillai A, Mumford RA, Stockley RA. The relationship of the fibrinogen cleavage biomarker Aα-Val360 with
disease severity and activity in α1-antitrypsin deficiency. Chest 2015;148:382-8. DOI PubMed
31. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z α1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are
chemotactic in vivo. Am J Pathol 2005;166:377-86. DOI PubMed PMC
32. Sinden NJ, Sapey E, Walton GM, and Stockley RA. S85 neutrophil cell membrane expression of proteinase 3 and its relationship to
alpha-1-antitrypsin deficiency (A1ATD). Available from: https://thorax.bmj.com/content/67/Suppl_2/A41.3 [Last accessed on 9 Dec
2022].
33. Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic
activity, and susceptibility to inhibition. J Immunol 2000;165:3366-74. DOI PubMed
34. Borel F, Sun H, Zieger M, et al. Editing out five serpinA1 paralogs to create a mouse model of genetic emphysema. PNAS ;115:2788-
93. DOI PubMed PMC
35. Gudmann NS, Manon-Jensen T, Sand JMB, et al. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation
is elevated in chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2018;503:1284-90. DOI PubMed
36. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. Eur Respir J
2013;41:1042-50. DOI PubMed